Device Week, Jan. 31, 2019 – Livongo's Acquisition Of myStrength; FDA Evaluates Peripheral Paclitaxel Devices Study

In this edition of Device Week, Medtech Insight's Catherine Longworth chats with Marion Webb about Livongo's acquisition of behavioral health company myStrength and with Reed Miller about the controversy surrounding the meta-analysis finding of a higher mortality risk with paclitaxel-eluting peripheral devices. 

Listen to the podcast via the player below:

Open Media

Medtech Insight articles addressing topics discussed in this episode:

• SCAI, Manufacturers Defend Peripheral Paclitaxel Devices Against Doubts

• Livongo Buys Behavioral Health Firm in Multimillion Dollar Deal, Plans to Hire 300-500 People